Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature

Abstract excerpt

KRAS mutations occur frequently in colorectal cancers (CRC) and predict lack of response to anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapy. CRC BRAF mutations, most commonly at V600E, occur less than 10% of the time, and occur usually in KRAS wild-type tumors, and more frequently in microsatellite instable tumors. Concomitant KRAS and BRAF mutant CRCs are rare (occurring in 0.001%); BRAF...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Colorectal Cancer Treatments and Studies
• Share to Gastric Cancer Management and Outcomes
• Share to Genetic factors in colorectal cancer